Immunogenicity to Therapeutic Proteins: Impact on PK/PD and Efficacy
Journal Title: The AAPS Journal - Year 2012, Vol 14, Issue 2
Abstract
The development of therapeutic proteins requires the understanding of the relationship between the dose, exposure, efficacy, and toxicity of these molecules. Several intrinsic and extrinsic factors contribute to the challenges for measuring therapeutic proteins in a precise and accurate manner. In addition, induction of an immune response to therapeutic protein results in additional complexities in the analysis of the pharmacokinetic profile, toxicity, safety, and efficacy of this class of molecules. Assessment of immunogenicity of therapeutic proteins is a required aspect of regulatory filings for a licensing application and for the safe and efficacious use of these compounds. A systematic strategy and well-defined criteria for measuring anti-drug antibodies (ADA) have been established, to a large extent, through coordinated efforts. These recommendations are based on risk assessment and include the determination of ADA content (concentration/titer), affinity, immunoglobulin isotype/subtype, and neutralization capacity. This manuscript reviews the requirements necessary for understanding the nature of an ADA response in order to discern the impact of immunogenicity on pharmacokinetics/pharmacodynamics and efficacy.
Authors and Affiliations
Narendra Chirmule, Vibha Jawa, Bernd Meibohm
Keywords
Related Articles
- EP ID EP681218
- DOI 10.1208/s12248-012-9340-y
- Views 86
- Downloads 0
Integrated Pharmacokinetic-Driven Approach to Screen Candidate Anticancer Drugs for Brain Tumor Chemotherapy
The online version of this article (doi:10.1208/s12248-012-9428-4) contains supplementary material, which is available to authorized users.
Intranasal Delivery of Proteins and Peptides in the Treatment of Neurodegenerative Diseases
The blood–brain barrier (BBB) is a major impediment to the therapeutic delivery of peptides and proteins to the brain. Intranasal delivery often provides a non-invasive means to bypass the BBB. Advantages of usin...
Current industrial practices of assessing permeability and P-glycoprotein interaction
Combination of the in vitro models that are high throughput but less predictive and the in vivo models that are low throughput but more predictive is used effectively to evaluate the intestinal permeability and transport...
Modeling Disease Progression in Acute Stroke Using Clinical Assessment Scales
The online version of this article (doi:10.1208/s12248-010-9230-0) contains supplementary material, which is available to authorized users.
Commentary: Current Perspectives on the Aggregation of Protein Drugs